Squarepoint Ops LLC Immunovant, Inc. Transaction History

Squarepoint Ops LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$25.1 - $31.61 $65,636 - $82,660	2,615 Added 5.6%	49,288 $1.3 Million
Q1 2024 May 15, 2024	BUY	$30.27 - $43.79 $1.41 Million - $2.04 Million	46,673 New	46,673 $1.51 Million
Q1 2023 May 15, 2023	BUY	$15.27 - $19.72 $900,059 - $1.16 Million	58,943 Added 168.64%	93,895 $1.46 Million
Q4 2022 Feb 14, 2023	BUY	$6.59 - $17.75 $230,333 - $620,398	34,952 New	34,952 $620,000
Q2 2022 Aug 15, 2022	SELL	$3.38 - $5.65 $94,765 - $158,409	-28,037 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$5.06 - $8.77 $201,787 - $349,738	-39,879 Reduced 58.72%	28,037 $154,000
Q4 2021 Feb 14, 2022	SELL	$7.33 - $9.32 $75,968 - $96,592	-10,364 Reduced 13.24%	67,916 $579,000
Q3 2021 Nov 15, 2021	BUY	$7.01 - $11.37 $300,546 - $487,477	42,874 Added 121.09%	78,280 $680,000
Q2 2021 Aug 16, 2021	SELL	$9.4 - $16.85 $107,526 - $192,747	-11,439 Reduced 24.42%	35,406 $374,000
Q1 2021 May 17, 2021	BUY	$13.08 - $49.6 $319,910 - $1.21 Million	24,458 Added 109.25%	46,845 $751,000
Q4 2020 Feb 16, 2021	BUY	$36.36 - $52.71 $173,691 - $251,795	4,777 Added 27.13%	22,387 $1.03 Million
Q3 2020 Nov 16, 2020	BUY	$22.61 - $38.9 $398,162 - $685,029	17,610 New	17,610 $620,000

212

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

Stay updated on Squarepoint Ops LLC with notifications on news.